ABSTRACT OBJECTIVES This multicenter pragmatic investigation assessed outcomes following clinical implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention (PCI).
T reatment with a P2Y 12 trials, respectively (8, 9) . Post hoc genetic analyses from these trials showed no effect of CYP2C19 genotype on outcomes with either prasugrel or ticagrelor (7, 10) . However, both drugs are more expensive than clopidogrel, which is available generically, and are associated with an increased bleeding risk. Ticagrelor is also associated with more frequent discontinuation because of side effects compared with clopidogrel (8) .
Although several institutions have implemented clinical CYP2C19 genotyping to guide antiplatelet therapy selection after PCI (11) (12) (13) (14) , the effect of this strategy on clinical outcomes is not well defined. Outcomes of Genotype-Guided Antiplatelet Therapy 
Cavallari et al. Kaplan-Meier plots were generated to estimate the cumulative risk for an event comparing patients in the LOF-clopidogrel versus LOF-alternative groups and also patients in the non-LOF versus LOF-alternative groups. To adjust for differences between groups, we used logistic regression to estimate the probability (propensity score) of receiving clopidogrel versus alternative antiplatelet therapy using previously reported risk factors for cardiovascular events and study site (2) . Propensity scores were estimated separately for each comparison. Stabilized inverse probability of treatment weights (IPTWs) were calculated using the estimated propensity score (21) . Covariate balance between groups was assessed by examining the magnitude of any residual differences between groups after applying the weights. Differences were Values are mean AE SD or n (%). LOF-clopidogrel patients were those with at least 1 LOF allele (e.g., *2, *3) treated with clopidogrel. LOF-alternative patients were those with at least 1 LOF allele (e.g., *2, *3) treated with prasugrel, ticagrelor, or high-dose clopidogrel. Non-LOF patients were those with no LOF allele: *1/*1, *1/*17, or *17/*17 genotype. *p < 0.05 compared with LOF-alternative group. †Pre-PCI P2Y12 inhibitor was defined as the drug used for loading; if the drug used for loading was not reported, the P2Y12 inhibitor on admission was used. ‡One patient had a stent placed, but no data were provided on the type of stent. §Chronic kidney disease was defined as estimated creatinine clearance (on the basis of the Cockcroft-Gault formula) <60 ml/min. kLeft ventricular EF, as measured during cardiac catheterization, was available for 1,274 patients.
ACE ¼ angiotensin-converting enzyme; ACS ¼ acute coronary syndrome; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; EF ¼ ejection fraction; LOF ¼ loss-of-function; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction; TIA ¼ transient ischemic attack.
quantified as the weighted standardized differences, for which a threshold of 10% was used to signify a meaningful difference in covariates (21) . We also examined the weights themselves to ensure that no observations were overly influential. To compare risk for primary and secondary outcomes, we constructed cause-specific Cox proportional hazard models, weighted by IPTWs. As a sensitivity analysis, we also estimated cluster robust standard errors by accounting for clustering by study site. All statistical analyses were performed in SAS version 9.4 (SAS Institute, Cary, North Carolina).
A total sample size of 1,815 patients, with at least 30% having an LOF allele and 60% of LOF allele carriers receiving alternative therapy, provided Table 3) . There was no difference in event rates between the non-LOF and LOF-alternative groups (13.7 vs. 8.7 per 100 patient-years; log-rank p ¼ 0.15; propensity score-adjusted HR: 1.14; 95% CI: 0.69 to 1.88; p ¼ 0.60) ( Table 3) . Similarly, within the non-LOF group, there was no difference in MACE rates between non-LOF patients treated with clopidogrel versus non-LOF patients treated with alternative therapy after adjusting for clinical differences between groups (adjusted HR: 1.01; 95% CI: 0.52 to 1.94; p ¼ 0.98) (Online Tables 3 and 4) . Accounting for within-site clustering did not change the estimates for the primary outcome (Online Table 5 ).
In the 518 patients with the IM phenotype only, the risk for a MACE was significantly higher with clopidogrel versus alternative antiplatelet therapy Secondary outcomes are shown in Table 3 .
The risk for a MACE plus other ischemic events 225 mg/day, n ¼ 6). †Alternative therapy in the non-LOF group consisted of prasugrel (n ¼ 125) or ticagrelor (n ¼ 68). ‡p < 0.001 for use of alternative therapy in the non-LOF group compared with the LOF group. APT ¼ antiplatelet therapy; PCI ¼ percutaneous coronary intervention.
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Cavallari et al. Table 4 Values are mean AE SD or n (%). *Weighted absolute standardized differences were calculated using stabilized inverse probability of treatment weighting. All values are <0.1, which indicates elimination of imbalance between the 2 groups. †Estimated creatinine clearance using the Cockcroft-Gault formula.
GFR ¼ glomerular filtration rate; MI ¼ myocardial infarction; PPI ¼ proton pump inhibitor; PVD ¼ peripheral vascular disease; other abbreviations as in Table 1 .
and LOF-alternative (4.6%) groups (Table 3) Unadjusted proportion of patients experiencing events during follow-up (%), event rate (per 100 patient-years), adjusted HR, and 95% CI are reported. The HR was adjusted with inverse probability weights derived from exposure propensity scores. Refer to Table 2 for variables included in the propensity score. Event rates were calculated as the number of events divided by follow-up time from index PCI to MACE or censoring in patient-years and are presented as medians. The median length of follow-up was 7.3 months (IQR: 1.5 to 10.9 months), 1.8 months (IQR: 0.2 to 8.2 months), and 4.5 months (IQR: 0.5 to 9.7 months) in the LOF-alternative, LOF-clopidogrel, and non-LOF groups, respectively (p < 0.001). LOF-clopidogrel patients had at least 1 LOF allele (e.g., *2, *3) treated with clopidogrel. LOF-alternative patients had at least 1 LOF allele (e.g., *2, *3) treated with prasugrel (n ¼ 222), ticagrelor (n ¼ 116), or high-dose clopidogrel (n ¼ 8). Non-LOF patients had no LOF allele: *1/*1, *1/*17, or *17/*17 genotypes. *Median event rate expressed as events per 100 patient-years. †Composite of a MACE (defined as first occurrence of myocardial infarction, ischemic stroke, or death) plus stent thrombosis and unstable angina.
CI ¼ confidence interval; HR ¼ hazard ratio; IQR ¼ interquartile range; MACE ¼ major adverse cardiovascular events; other abbreviations as in Tables 1 and 2 .
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